Anticipate generic drug launch
Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Find generic entry opportunities
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension|
|Abstract:||The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.|
|Inventor(s):||Stjernschantz; Johan Wilhelm (Uppsala, SE), Resul; Bahram (Uppsala, SE)|
|Assignee:||Pharmacia Aktiebolag (Stolkholm, SE)|
Patent Claim Types:|
see list of patent claims
|Use; Composition; Compound;|
Back Citations: 37th percentile
Forward Citations: 1st percentile
|Patent Number||Expiration Date|
|6,429,226||August 06, 2010|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|European Patent Office||0364417||<disabled in preview>||61/1997||Austria||<disabled>|
|European Patent Office||0364417||<disabled in preview>||9690031-1||Sweden||<disabled>|
|European Patent Office||0364417||<disabled in preview>||97C0111||Belgium||<disabled>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.